Gilead 2Q Revenues: $8.2 billion (+26%) 2Q Earnings: $4.5 billion (+23%) FY Revenues: $15.8 billion (+37%) FY Earnings: $8.8 billion (+50%) Comments: Antiviral product sales increased to $7.6 billion in the quarter, up 27% driven by Hep C drug Harvoni(with sales of $3.6 billion in the quarter and $7.2 billion YTD), which was approved in the U.S. and Europe in 4Q14, partially offset by a decrease in sales of Sovaldi (down 63% to $1.3 billion) due primarily to the uptake in Harvoni...